Skip to content

Asset turnover at other companies

Guardant Health logo
Guardant HealthGH
0.7×+0.2×
Natera, Inc. logo
Natera, Inc.NTRA
1.2×0.0×
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
0.1×-0.4×
Veracyte logo
VeracyteVCYT
0.4×0.0×
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
0.1×0.0×
GeneDx Holdings logo
GeneDx HoldingsWGS

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$2.76B+93.6%
Enterprise value$2.89B+78.0%
P/S9.3×+1.8×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity-0.2×
Current ratio3.4×+0.4×

Where this comes from

Calculated from Adaptive Biotechnologies’s reported figures.

Based on trailing twelve months.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's asset turnover?
Adaptive Biotechnologies (ADPT) reported asset turnover of 0.6× in Q1 2026.
How has Adaptive Biotechnologies's asset turnover changed year-over-year?
Adaptive Biotechnologies's asset turnover increased by 73.4% year-over-year, from 0.3× to 0.6×.
What is the long-term trend for Adaptive Biotechnologies's asset turnover?
Over 5 years (2020 to 2025), Adaptive Biotechnologies's asset turnover has grown at a 40.3% compound annual growth rate (CAGR), from 0.1× to 0.5×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.